HK Stock Market Move | KEYMED BIO-B (02162) rose nearly 6% again, Sipuleucel-T had rapid sales growth last year, global value realization path clear.

KEYMED BIO-B(02162) rose nearly 6%, as of the time of publication, it rose 5.97% to 71 Hong Kong dollars, with a turnover of 415 million Hong Kong dollars. On the news front, the 2025 performance of Connoa showed that the company achieved annual revenue of 720 million RMB, of which the sales revenue of Kangyueda (Situximab) was about 315 million RMB, and the cooperative revenue was 402 million RMB. Earlier, Connoa announced that its NewCo cooperative enterprise Ouro Medicines has signed a merger agreement with Gilead Sciences. Gilead will acquire Ouro Medicines through a merger, with a transaction amount including a debut payment of 1.675 billion US dollars and a maximum of 500 million US dollars in milestone payments, with a total transaction amount of up to 2.175 billion US dollars. Huatai pointed out that considering its three major indications being included in medical insurance, good pricing, and rapid progress in hospitalization, it is optimistic about the rapid growth of sales in 2026. At the same time, the company's global value realization path is further clarified. Open Source Securities noted that Connoa achieved rapid growth in revenue end with the rapid increase in sales of its flagship product Situximab and the confirmation of upfront payments for licensed products. Considering that the company's partner Ouro Medicines (holding a 15% stake) has been acquired by Gilead, the company will receive approximately 250 million US dollars in upfront payments after the completion of the transaction, which will strengthen the company's future performance.